{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T12:40:52.952060+00:00","company":{"ticker":"PHAT","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc."},"pagination":{"limit":100,"returned":5,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"5041010f01ae977cd374a48ce01a91e7a75d704a","cik":1783183,"ticker":"PHAT","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2026-04-30T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2026","report_date":"2026-04-30","result_type":"reported_results","revenue_text":"$58.3 million"},"claim":"Phathom Pharmaceuticals, Inc. reported the first quarter ended March 31, 2026 results: revenue $58.3 million. Guidance reaffirmed.","evidence_excerpt":"Exhibit 99.1 Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update • ~1.35 million total\nVOQUEZNA ® prescriptions filled to date • $58.3 million in Q1 net revenues, a 104% increase year-over-year • Q1 operating expenses of $61.8 million; non-GAAP operating expenses of $56.2 million and net cash usage of ~$15 million,","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001193125-26-193945","anchor_url":"https://secwatch.observer/filing/0001193125-26-193945#claim-5041010f01ae977cd374a48ce01a91e7a75d704a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312526193945/0001193125-26-193945-index.htm"},{"fact_type":"executive_change","fact_key":"b747951331","cik":1783183,"ticker":"PHAT","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2025-04-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-04-16","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Theodore R. Schroeder was appointed as Director at Phathom Pharmaceuticals, Inc..","evidence_excerpt":"The board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) appointed Theodore R. Schroeder to the Board as a Class I director, effective April 16, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-082089","anchor_url":"https://secwatch.observer/filing/0001193125-25-082089#claim-b747951331","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525082089/0001193125-25-082089-index.htm"},{"fact_type":"executive_change","fact_key":"f9fe0a5d5a","cik":1783183,"ticker":"PHAT","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2025-04-01T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-04-01","interim":false,"role":"Chief Executive Officer, President and Class I director","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Steven Basta was appointed as Chief Executive Officer, President and Class I director at Phathom Pharmaceuticals, Inc..","evidence_excerpt":"Steven Basta was appointed as the Chief Executive Officer, President and as a Class I director of Phathom Pharmaceuticals, Inc. (the “Company”), replacing Terrie Curran who resigned as President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”) for personal reasons, effective March 31, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-069748","anchor_url":"https://secwatch.observer/filing/0001193125-25-069748#claim-f9fe0a5d5a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525069748/0001193125-25-069748-index.htm"},{"fact_type":"executive_change","fact_key":"08c3c0237f","cik":1783183,"ticker":"PHAT","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2025-04-01T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-03-31","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"Steven Basta","successor_named":true},"claim":"Terrie Curran resigned as President and Chief Executive Officer at Phathom Pharmaceuticals, Inc..","evidence_excerpt":"Terrie Curran who resigned as President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”) for personal reasons, effective March 31, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-069748","anchor_url":"https://secwatch.observer/filing/0001193125-25-069748#claim-08c3c0237f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525069748/0001193125-25-069748-index.htm"},{"fact_type":"earnings_release","fact_key":"835e7f8078acce5285ff176fdb63655506499140","cik":1783183,"ticker":"PHAT","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the first quarter 2024 was $82.9 million","period_text":"the first quarter of 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":"Net revenues for the first quarter 2024 were $1.9 million"},"claim":"Phathom Pharmaceuticals, Inc. reported the first quarter of 2024 results: revenue Net revenues for the first quarter 2024 were $1.9 million, net income Net loss for the first quarter 2024 was $82.9 million.","evidence_excerpt":"Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the first quarter of 2024","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-134793","anchor_url":"https://secwatch.observer/filing/0001193125-24-134793#claim-835e7f8078acce5285ff176fdb63655506499140","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312524134793/0001193125-24-134793-index.htm"}]}